CMS Approves NTAP Reimbursement for Molecular Imaging Agent Cytalux
Through a new technology add-on payment (NTAP), the use of Cytalux will reportedly be reimbursed by CMS up to 65 percent of the cost of the molecular imaging agent, which is FDA-approved for intraoperative imaging of ovarian and lung cancer.
The Centers for Medicare and Medicaid Services (CMS) has granted a new technology add-on payment for Cytalux (On Target Laboratories), an intraoperative molecular imaging agent indicated for assessment of lung and ovarian cancer.
The NTAP payment, which goes into effect on October 1, 2023, will reportedly provide hospitals with reimbursement of up to 65 percent of the cost of Cytalux with a maximum payment of $2,762.50, according to On Target Laboratories.
“We are thrilled Cytalux has been granted NTAP for both lung and ovarian cancer indications,” noted Ben Lundgren, the chief executive officer of On Target Laboratories. “This approval reinforces the clinical benefits of Cytalux and will make our technology accessible to more patients.”
On Target Laboratories noted the molecular imaging agent was granted ICD-10-PCS codes in June 2023 and recently issued a level II HCPCS code from CMS to facilitate submission of hospital claims.
(Editor’s note: For related content, see “Cytalux Gets Expanded FDA Approval for Intraoperative Imaging of Lung Cancer.”)
